Precision Neuroscience
Precision Neuroscience is an Invasive Cortical Implants company founded in 2021 and based in New York, United States. It has raised $405M in total funding, most recently a Series D in 2026.
Founded in 2021 and headquartered in New York, Precision Neuroscience develops the Layer 7 Cortical Interface, a thin-film flexible electrode array that enables high-resolution neural recording via electrocorticography. The device is placed on the brain's surface through a minimally-invasive slot craniotomy and operates thousands of electrode sites without penetrating brain tissue. The Layer 7 interface received FDA 510(k) clearance in April 2025 for temporary implantation (up to 30 days) to support recording, monitoring, and stimulation during neurosurgical procedures. The company has already deployed the device in intraoperative placements across multiple human neurosurgery patients. Precision Neuroscience raised $250 million in Series D funding announced on September 25, 2026, bringing total capital raised to $405 million.
Precision Neuroscience addresses a core challenge in brain-computer interface development: achieving high-resolution neural recording with minimal surgical trauma. The Layer 7 interface's FDA clearance and demonstrated human deployment mark a clinical milestone for surface-based neural interfaces. With $405 million in total funding and a $250 million Series D, the company has secured substantial capital to advance commercialization of minimally-invasive BCI technology.
At a glance
Total raised
$405M
Headcount
51-200
Headquarters
New York
United StatesFounded
2021
Status
Private
Subsector
Where Precision Neuroscience ranks
Top 25 Brain-Computer Interfaces companies →Funding history
Total raised
$405M
Rounds tracked
4
Latest stage
Series D
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Sep 25, 2026 | Series D | $250M | — | — |
| Dec 16, 2024 | Series C | $102M | $500M | General Equity Holdings |
